ImmuneOnco Biopharma
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A biopharma developing innate immune checkpoint inhibitors, with a first-in-class CD47-targeting molecule in clinical trials.
OncologyImmunology
Technology Platform
Proprietary antibody engineering platform focused on innate immune checkpoints, particularly the phagocytosis pathway (e.g., CD47-SIRPα).
Opportunities
First-mover potential in China for a differentiated CD47 inhibitor with a potentially better safety profile in a high-value oncology market.
Risk Factors
Clinical validation risk for a novel innate immune mechanism and potential for serious hematological side effects that could derail development.
Competitive Landscape
A key player in the competitive CD47 inhibitor space, racing to demonstrate clinical advantage over other mechanisms and competitors.